Protein 'Heroes' Block Genetic Mutations

November 12, 1997

REHOVOT, Israel, November 12, 1997 -- Researchers at the Weizmann Institute of Science have discovered that two repair proteins perform a truly "heroic" act, stopping genetic mutations dead in their tracks.

In a study reported in the November 14 issue of the *Journal of Biological Chemistry* (Vol.272, pp. 28906-28911), Weizmann Institute researchers describe how these proteins "fling themselves" onto damaged genes, which, if replicated, lead to the formation of mutations.

Mutations are changes in DNA that can cause cancer by turning on cancer-causing genes or turning off the genes that suppress cancer.

"If we can fully understand this and other natural DNA repair mechanisms, we may one day be able to turn them on as required in order to prevent cancer," says research team leader Prof. Zvi Livneh of the Weizmann Institute's Department of Biological Chemistry. He conducted the study with Dr. Tamar Paz-Elizur and doctoral student Yoav Barak.

Protein valor

DNA damage is a normal part of the life of a cell. Carcinogens, such as ultraviolet radiation or the chemicals in cigarette smoke, routinely damage DNA, leading to numerous mutations.

Luckily, DNA can repair itself, relying on proteins known as repair enzymes. These enzymes literally cut out the damaged parts of the DNA and replace them with healthy DNA material. Without them, life on earth would be impossible because mutations would go haywire.

Sometimes, however, the damaged DNA escapes repair and a cascade of events leading to cancerous growth can begin. This is precisely where our two heroic proteins, known as Fpg and UvrA, step in.

These proteins were previously known to play a role in cut-and-paste DNA repair jobs. But now Prof. Livneh's team has discovered that they are capable of a far more valiant task. By hurling themselves onto the damaged DNA and physically attaching themselves to it, these proteins can prevent the damaged site from multiplying and causing a mutation.

According to the scientists, the two "heroic" proteins may be part of a larger family of DNA repair proteins that work on the same principle. This mechanism provides a second line of defense against the mutation and gives the cell a crucial second chance at healthy growth.

"The proteins block the road to replication like demonstrators throwing themselves down on the road to block traffic," says Prof. Livneh. "When a protein sits on the lesion and directly binds itself onto the site of the damage, the mutation cannot be formed."

Only when this emergency defense mechanism fails, can malignant transformation begin.

Building up natural defenses

Weizmann scientists discovered the new role of the two proteins by analyzing E coli bacteria. They will follow up this research by analyzing human cells, Prof. Livneh says.

Every human body contains different kinds and quantities of repair proteins. In each individual they vary in their rate of repair. When scientists learn more about these proteins -- determining, for example, which proteins repair what kinds of damage -- they may be able to strengthen people's own natural defenses.

Scientists may also one day be able to identify people whose bodies aren't as effective as others at repairing DNA. For example, they may be able to warn people who are more prone to genetic defects induced by ultraviolet radiation to avoid excessive exposure to sunlight.

This research was funded in part by the Scheuer Research Foundation of the Israel Academy of Sciences and Humanities, the Israel Ministry of Science, and the Leo and Julia Forchheimer Center for Molecular Genetics at the Weizmann Institute.

If you'd like to see the Journal piece, speak with Prof. Livneh, or get his email userid,

Contact: Julie Osler, Director of Pubic Affairs

American Committee for the Weizmann Institute of Science

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to